Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

Pipeline Report | <b>Pipeline Report: September 2020</b>

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the phase 2 LIO-1 trial (NCT04042116) evaluation of lucitanib and nivolumab (Opdivo) across different gynecologic cancer subtypes.

The phase 2 portion of the LIO-1 trial will examine the combination in several gynecologic cohorts, according to Hamilton. These cohorts include patients with ovarian cancer, endometrial cancer, and cervical cancer, with a fourth cohort examining the combination in patients with clear cell cancer, of either endometrial or ovarian origin. Investigators will begin with a 6-mg dose and increase to 8 mg and 10 mg, as tolerated by patients, Hamilton concludes.